March 3, 2026 — Leads & Copy — Vistagen (Nasdaq: VTGN), a biopharmaceutical company in late clinical stages, announced its participation in investor conferences this March. The company focuses on neuroscience by using nose-to-brain neurocircuitry to develop and commercialize pherines, a new class of intranasal product candidates.
Vistagen will attend the Leerink Healthcare Conference from March 9-11, 2026, in Miami, FL. The format will be one-on-one meetings.
The company will also participate in the Stifel 2026 Virtual CNS Forum on March 17, 2026, at 9:00 AM EDT. President and CEO Shawn Singh will hold a fireside chat, and there will be one-on-one meetings.
The Stifel CNS presentation will be available via live webcast on the “Events” page in the Investors section of Vistagen’s website. A replay will be available after the presentation.
Vistagen is working to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates aim to provide therapeutic benefits without the need for absorption into the blood or uptake into the brain. The company’s pherine pipeline includes five investigational product candidates that focus on improving the current standard of care for conditions such as social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause.
Source: Vistagen
